We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+12.4%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$237M
AUM Growth
+$61.7M
Cap. Flow
+$42.4M
Cap. Flow %
17.92%
Top 10 Hldgs %
29.74%
Holding
101
New
35
Increased
9
Reduced
16
Closed
26

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$7.31M
2
BRKR icon
Bruker
BRKR
+$5.5M
3
LIVN icon
LivaNova
LIVN
+$4.1M
4
SPNC
Spectranetics Corp
SPNC
+$3.7M
5
COO icon
Cooper Companies
COO
+$3.58M

Top Sells

Rank Stock Value
1
SYK icon
Stryker
SYK
+$5.02M
2
BHC icon
Bausch Health
BHC
+$4.13M
3
CYBX
CYBERONICS INC
CYBX
+$3.65M
4
ABT icon
Abbott
ABT
+$3.22M
5
VAR
Varian Medical Systems, Inc.
VAR
+$2.95M

Sector Composition

Rank Sector Weight
1 Healthcare 56.19%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIEN
51
DELISTED
Sientra, Inc.
SIEN
$1.83M 0.77%
+30,930
New +$1.61M
DCOY
52
Decoy Therapeutics
DCOY
$2.05M
– –
0
– –
TNXP icon
53
Tonix Pharmaceuticals
TNXP
$191M
– –
0
– –
AVNS
54
DELISTED
Avanos Medical
AVNS
$1.49M 0.63%
+44,573
New +$1.39M
XENT
55
DELISTED
Intersect ENT, Inc
XENT
$1.24M 0.52%
+55,000
New +$1.09M
ADYX
56
DELISTED
Adynxx Inc
ADYX
$1.12M 0.47%
8,717
– –
ATRC icon
57
AtriCure
ATRC
$2.19B
$1.09M 0.46%
+48,450
New +$998K
AKRX
58
DELISTED
Akorn Inc
AKRX
$1.06M 0.45%
28,500
-21,700
-43% -$679K
ALGN icon
59
PUT
Align Technology
ALGN
$12.4B
$986K 0.42%
+55,000
New +$3.53M
TNDM icon
60
Tandem Diabetes Care
TNDM
$1.63B
$979K 0.41%
+8,287
New +$822K
ZGNX
61
DELISTED
Zogenix, Inc.
ZGNX
$866K 0.37%
58,750
– –
FOMX
62
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$827K 0.35%
102,000
– –
ARAY icon
63
CALL
Accuray
ARAY
$35.1M
$675K 0.28%
+100,000
New +$643K
WMGIZ
64
DELISTED
Wright Medical Group, Inc. Contingent Value Right
WMGIZ
$596K 0.25%
+585,436
New +$596K
FPRX
65
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$560K 0.24%
+13,500
New +$453K
DMK
66
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$435K 0.18%
1,150
– –
OCRX
67
DELISTED
Ocera Therapeutics, Inc.
OCRX
$409K 0.17%
131,000
– –
ALDX icon
68
Aldeyra Therapeutics
ALDX
$91.7M
$390K 0.16%
57,500
– –
CBAY
69
DELISTED
Cymabay Therapeutics
CBAY
$338K 0.14%
200,000
– –
GI
70
DELISTED
EndoChoice Holdings, Inc.
GI
$334K 0.14%
+40,000
New +$384K
ALIM
71
DELISTED
Alimera Sciences
ALIM
$314K 0.13%
8,640
+5,626
+187% +$244K
RCKT icon
72
Rocket Pharmaceuticals
RCKT
$378M
$304K 0.13%
6,700
– –
SPNC
73
CALL
DELISTED
Spectranetics Corp
SPNC
$301K 0.13%
20,000
-270,000
-93% -$3.56M
KALV
74
DELISTED
KalVista Pharmaceuticals
KALV
$290K 0.12%
5,714
– –
SRPT icon
75
CALL
Sarepta Therapeutics
SRPT
$1.89B
$208K 0.09%
5,400
– –
1 2
3
4

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2015 Portfolio in Review

As of Q4 2015, Pura Vida Investments held 101 positions worth $237M, up 35% from $175M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Pura Vida Investments deployed $42.4M of net new capital in Q4 2015, opening 35 new positions and adding to 9 existing holdings. Its largest new stake was Baxter International: 200,000 shares worth $7.63M.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 66% a quarter earlier.

On the sell side, the largest reduction was Stryker, an estimated $5.02M trimmed.

  • Pura Vida Investments's largest Q4 2015 buy was Baxter International: 200,000 shares worth $7.63M.
  • Pura Vida Investments added most to Accendra Health in Q4 2015, an estimated $2.75M increase.
  • Pura Vida Investments's biggest Q4 2015 reduction was Stryker, cutting an estimated $5.02M.
  • Pura Vida Investments fully exited Bausch Health in Q4 2015, selling an estimated $4.13M.
  • Pura Vida Investments's ten largest holdings make up 30% of its $237M portfolio in Q4 2015.
  • Pura Vida Investments opened 35 new positions and closed 26 in Q4 2015.
  • Pura Vida Investments's portfolio value rose 35% quarter-over-quarter to $237M.

Based on Pura Vida Investments's 13F filing for Q4 2015, filed 16 Feb 2016.